Comparative Pharmacology
Head-to-head clinical analysis: BREVICON 28 DAY versus TAYTULLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVICON 28 DAY versus TAYTULLA.
BREVICON 28-DAY vs TAYTULLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive; ethinyl estradiol and norethindrone suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation. Additionally, alters cervical mucus consistency and endometrial lining to impede sperm penetration and implantation.
Combination of drospirenone, a spironolactone analog with antimineralocorticoid and antiandrogenic activity, and ethinyl estradiol, an estrogen. Suppresses gonadotropins, primarily luteinizing hormone, inhibiting ovulation. Increases cervical mucus viscosity and alters endometrial receptivity.
One tablet (0.5 mg norethindrone and 35 mcg ethinyl estradiol) orally once daily for 28 days (21 active tablets followed by 7 inert tablets).
One capsule orally once daily for 24 weeks.
None Documented
None Documented
Norethindrone: 8-11 hours; Ethinyl estradiol: 13-27 hours; half-life for ethinyl estradiol allows once-daily dosing
Terminal elimination half-life: 30 hours. Provides once-daily dosing with steady-state achieved after 7 days.
Renal: ~40% as metabolites and unchanged drug; fecal/biliary: ~60% as metabolites
Renal: ~60% as unchanged drug; Fecal: ~40% as metabolites and unchanged drug.
Category C
Category C
Oral Contraceptive
Oral Contraceptive